What changed between these versions
A complete substitute amendment. v2 entirely replaces v1's provisions, shifting the focus from specific limits on compounding commercially available drug copies and enhanced oversight/fees for outsourcing facilities to new reporting requirements for serious adverse events and interstate dispensing, alongside new labeling mandates for compounded drug products.
Overview
Extensive changes throughout the bill, constituting a complete rewrite of the operative text. · v2 fundamentally restructures the bill's approach to regulating compounding pharmacies and outsourcing facilities, introducing new reporting and labeling requirements while removing previous provisions related to compounding limits, outsourcing facility inspections, and fees.
v2 is a complete substitute amendment that redefines the bill's regulatory scope. It entirely removes v1's provisions concerning limits on compounding copies of commercially available drugs, specific inspection mandates for large-scale outsourcing facilities, and changes to establishment fees. Instead, v2 introduces new requirements for reporting serious adverse events and interstate dispensing volumes for compounded drug products, along with mandatory labeling information for these products.
Major additions
This new subsection requires licensed pharmacists or physicians who compound drug products and send them out of the State where compounding occurs to submit reports of any serious adverse events associated with those compounded drug products to the Secretary, the State of compounding, and each State to which the drugs are sent. The content and format must follow established guidance or regulations.
This addition introduces a new, mandatory reporting mechanism for patient safety concerns related to compounded drugs dispensed across state lines. It aims to enhance federal and state oversight of adverse outcomes, providing critical data for risk assessment and regulatory action.
This new subsection mandates annual reporting for licensed pharmacists or physicians who compound drug products and send more than 5 percent of their total annual compounded products out-of-state. The report, due by January 15 each year, must identify the compounder's details and the total number of units of compounded drug products, by type and by month, sent to each applicable State. It also directs the Secretary to establish an information sharing system to reduce administrative burden.
This provision creates a new transparency mechanism for interstate compounding activities, allowing federal and state authorities to monitor the volume and types of compounded drugs being distributed across state lines. This data can inform regulatory resource allocation and identify potential areas of concern regarding large-scale interstate compounding.
This new subsection clarifies that nothing in Section 2 (d) should be construed to preempt any State or political subdivision requirement for additional, more stringent, or supplementary reporting with respect to compounded drug products.
This ensures that states retain the authority to impose stricter reporting requirements than those established federally, allowing for a layered regulatory approach and potentially higher safety standards in certain jurisdictions. It prevents federal requirements from being interpreted as a ceiling for regulation.
This new section amends Section 503A(b)(3) of the Federal Food, Drug, and Cosmetic Act to require specific information on the label of compounded drug products. This includes a statement that the medication has been compounded for an individual patient and has not been FDA-approved, adverse event reporting information (website and phone number), and any other information the Secretary may prescribe.
This addition significantly enhances patient transparency and awareness regarding compounded medications. By explicitly stating the non-FDA-approved status and providing clear adverse event reporting channels, it empowers patients with crucial information and facilitates the collection of safety data.
Deletions
This section amended Section 503A(b) of the Federal Food, Drug, and Cosmetic Act. It specifically limited pharmacies from compounding any drug product that is essentially a copy of a commercially available drug product more than 20 times in a single month. It also provided detailed definitions for 'essentially a copy of a commercially available drug product' and 'commercially available drug product'.
The deletion of this section removes the specific quantitative restriction on the compounding of drug products that are essentially copies of commercially available drugs. This eliminates a key regulatory mechanism aimed at preventing pharmacies from operating as de facto manufacturers of existing drugs without full FDA oversight.
This section inserted a new subsection (d) into Section 503A, requiring pharmacies, facilities, or physicians to submit an annual report if they compounded, more than 20 times in a single month for out-of-state patients, any drug product containing an active ingredient found in a commercially available drug product. The report would identify the type of drug and the total number of times it was compounded.
The deletion removes the specific reporting requirement tied to the volume of out-of-state compounding of commercially available drug copies. This eliminates a data collection point that would have informed regulators about the scale of this particular compounding practice.
This section proposed two main changes: (a) It mandated specific inspection requirements for 'large-scale outsourcing facilities' (defined as compounding more than 100 times in a calendar year), including an inspection prior to first compounding and biennial reinspections. (b) It removed the exemption for outsourcing facilities from general registration and reporting requirements under Section 510(g)(1) of the Act.
The deletion of this section removes proposed enhanced oversight and registration mandates for outsourcing facilities. This means that the specific requirements for pre-compounding and biennial inspections for large-scale facilities, and the general requirement for outsourcing facilities to register under Section 510(g)(1), are no longer part of the bill.
This section amended Section 744K(c)(1)(A)(i) of the Federal Food, Drug, and Cosmetic Act to change the base establishment fee for outsourcing facilities from a fixed '$15,000' to 'a base amount deemed appropriate by the Secretary to fund activities to ensure the safety of compounded drug products'.
The deletion of this section removes the proposed change to the base establishment fee for outsourcing facilities. This means the fee remains at the existing statutory amount (likely $15,000, though the bill text only shows the striking of this amount) and the Secretary does not gain the discretion to adjust it to fund safety activities.
Scope
Complete substitute — Changes are scattered throughout the bill's original structure, as the entire operative text of v1 was replaced with new provisions. — v2 represents a significant change in policy direction. While both versions aim to regulate compounding, v1 focused on limiting specific compounding practices and increasing oversight/fees for outsourcing facilities, whereas v2 shifts to adverse event reporting, interstate dispensing transparency, and mandatory labeling. — The new reporting requirements in v2's Section 2 (d)(1) and (d)(2) add new compliance obligations for licensed pharmacists and physicians who compound drug products and send them out of state, interacting with the existing framework of Section 503A. Similarly, the new labeling requirements in v2's Section 3 modify the existing requirements under Section 503A(b)(3). The rule of construction in Section 2(d)(3) clarifies the interaction with state laws.
Impact analysis
Licensed pharmacists and physicians who compound drug products and send them out of state
Procedural change and increased transparency. The previous specific restrictions are removed, but new, broader reporting and labeling duties are imposed, focusing on patient safety and interstate activity.
In v1, this group faced potential limits on compounding commercially available drug copies and a specific reporting requirement if exceeding 20 out-of-state copies per month. In v2, these specific limits and reporting are removed. Instead, they are now required to report serious adverse events associated with compounded drugs and to report annually on interstate dispensing volumes if more than 5% of their total annual compounded products are sent out-of-state.
Outsourcing facilities (as defined in Section 503B(d)(4))
Reduced regulatory burden compared to v1's proposals. The specific new oversight mechanisms for outsourcing facilities envisioned in v1 are no longer present in v2.
In v1, 'large-scale outsourcing facilities' (compounding >100 times/year) would have faced mandatory pre-compounding and biennial inspections, and all outsourcing facilities would have lost their exemption from registration and reporting requirements under Section 510(g)(1). In v2, all these provisions related to outsourcing facilities are deleted.
Patients receiving compounded drug products
Increased information and safety mechanisms.
In v1, patients might have indirectly benefited from limits on compounding copies of commercially available drugs and enhanced oversight of outsourcing facilities. In v2, patients will directly benefit from new labeling requirements that clearly state the drug is compounded and not FDA-approved, and provides information for adverse event reporting. They also benefit from the new serious adverse event reporting requirements.
The Secretary of Health and Human Services (FDA)
Shift in regulatory focus and data collection. The Secretary's role shifts from enforcing specific compounding limits and facility oversight to managing adverse event and interstate dispensing data, and ensuring labeling transparency.
In v1, the Secretary would have gained new reporting data on commercial drug copies compounded out-of-state, new inspection authority over large-scale outsourcing facilities, and discretion to set a new base establishment fee. In v2, the Secretary gains new reporting data on serious adverse events and interstate dispensing volumes, and authority to prescribe the form and manner of these reports, as well as additional labeling information.